Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Medicus Pharma Ltd

MDCX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$0.28

▼ -20.88%

Market Cap $17.70M · Vol 150.41K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$17.70M

Micro Cap

Div Yield

N/A

EPS Growth

+79.11%

YoY

RSI (14)

43.21

Momentum

Beta

N/A

vs Market

52W High

$3.00

90.66% below

52W Low

$0.25

12.04% above

Volume

150.41K

Avg 120.08K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

88.81%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Medicus Pharma Ltd (MDCX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MDCX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.51%

-23.01%

-16.88%

-73.58%

YTD

-81.69%

-85.85%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-35,444,360.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-451.28% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+79.11%
Outstanding Shares	63.18M

Technical Indicators

50-Day SMA	$0.37
200-Day SMA	$0.94
RSI (14)	43.21
Beta	N/A
52-Week High	$3.00
52-Week Low	$0.25

Volume Today	150.41K
Avg Daily Volume (30D)	120.08K
Relative Volume	1.25x
Volatility (10D)	143.28
Volatility (30D)	125.69
Free Float	88.81%

Analyst Consensus

BUY

Current Price $0.28

Mean Target $4.50

52W Low$0.25 52W High$3.00

Current

Target

$0.25 $3.00

Current Analyst target

+1,506.57% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01JPD08P6

ISINCA58471K2020

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateDec 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.